title: Reassessing the cardiovascular risks and benefits of thiazolidinediones.
abstract: This article is designed for the general cardiologist, endocrinologist, and internist caring for patients with diabetes and coronary artery disease. Despite the burden of coronary disease in diabetics, little is known about the impact of commonly used oral hypoglycemic agents on cardiovascular outcomes. As the untoward effects of insulin resistance (IR) are increasingly recognized, there is interest in targeting this defect. Insulin resistance contributes to dyslipidemia, hypertension, inflammation, hypercoagulability, and endothelial dysfunction. The aggregate impact of this process is progression of systemic atherosclerosis and an increased risk of adverse cardiovascular outcomes. As such, much attention has been paid to the peroxisome-proliferator-activated receptor gamma (PPARg) agonists rosiglitazone and pioglitazone (thiazolidinediones [TZDs]). Many studies have demonstrated a beneficial effect on the atherosclerotic process; specifically, these agents have been shown to reduce markers of inflammation, retard progression of carotid intimal thickness, prevent restenosis after coronary stenting, and prevent cardiovascular death and myocardial infarction in 1 large trial. Such benefits come at the risk of fluid retention and heart failure (HF) exacerbation, and the net effect on plasma lipids is still poorly understood. Thus, the aggregate risk-benefit ratio is poorly defined. A recent meta-analysis has raised significant concerns regarding the overall cardiovascular safety of 1 particular PPARg agonist (rosiglitazone), prompting international debate and regulatory changes. This review scrutinizes the clinical evidence regarding the cardiovascular risks and benefits of PPARg agonists. Future studies of PPARg agonists, and other emerging drugs that treat IR and diabetes, must be designed to look at cardiovascular outcomes.
authors.affiliation: The Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA. zinnao1@med.nyu.edu
authors.forename: Andrew
authors.initials: A
authors.lastname: Zinn
authors.forename: Sabrina
authors.initials: S
authors.lastname: Felson
authors.forename: Edward
authors.initials: E
authors.lastname: Fisher
authors.forename: Arthur
authors.initials: A
authors.lastname: Schwartzbard
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000503:physiopathology; D047495:PPAR gamma / Q000819:agonists / Q000494:pharmacology; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone
references.citation: N Engl J Med. 1993 Sep 30;329(14):977-86
references.pmid: 8366922
references.citation: N Engl J Med. 2005 Dec 22;353(25):2643-53
references.pmid: 16371630
references.citation: N Engl J Med. 2007 Jun 14;356(24):2457-71
references.pmid: 17517853
references.citation: Am Heart J. 2005 Jan;149(1):20-32
references.pmid: 15660031
references.citation: Am J Cardiol. 2002 Feb 1;89(3):318-22
references.pmid: 11809434
references.citation: Clin Ther. 2004 Mar;26(3):379-89
references.pmid: 15110130
references.citation: J Clin Endocrinol Metab. 2001 Jul;86(7):3452-6
references.pmid: 11443224
references.citation: Am J Cardiol. 2002 Nov 1;90(9):947-52
references.pmid: 12398960
references.citation: Diabetes Care. 2004 Nov;27(11):2654-60
references.pmid: 15505001
references.citation: Diabetologia. 2005 Sep;48(9):1726-35
references.pmid: 16025252
references.citation: Am Heart J. 2003 Aug;146(2):E5
references.pmid: 12891212
references.citation: N Engl J Med. 2006 Oct 12;355(15):1551-62
references.pmid: 16980380
references.citation: Diabetes Care. 2005 Jul;28(7):1547-54
references.pmid: 15983299
references.citation: Circulation. 2005 Nov 1;112(18):2792-8
references.pmid: 16246947
references.citation: Arterioscler Thromb Vasc Biol. 2004 May;24(5):930-4
references.pmid: 15001452
references.citation: Circulation. 2005 May 17;111(19):2525-31
references.pmid: 15883215
references.citation: N Engl J Med. 2007 Aug 30;357(9):844-6
references.pmid: 17687124
references.citation: JAMA. 2002 Jan 16;287(3):356-9
references.pmid: 11790215
references.citation: Lancet. 1998 Sep 12;352(9131):837-53
references.pmid: 9742976
references.citation: Lancet. 2005 Oct 8;366(9493):1279-89
references.pmid: 16214598
references.citation: JAMA. 2006 Dec 6;296(21):2572-81
references.pmid: 17101640
references.citation: Am J Cardiol. 2006 Jun 19;97(12A):20G-30G
references.pmid: 16813735
references.citation: Lancet. 2006 Sep 23;368(9541):1096-105
references.pmid: 16997664
references.citation: Circulation. 2005 Feb 8;111(5):583-90
references.pmid: 15699279
references.citation: Physiol Rev. 1995 Jul;75(3):473-86
references.pmid: 7624391
references.citation: Diabetologia. 2004 Sep;47(9):1519-27
references.pmid: 15322749
references.citation: N Engl J Med. 2004 Sep 9;351(11):1106-18
references.pmid: 15356308
references.citation: Am Heart J. 2006 Jul;152(1):27-38
references.pmid: 16824829
references.citation: J Am Coll Cardiol. 2000 Nov 1;36(5):1529-35
references.pmid: 11079654
references.citation: Lancet. 1998 Sep 12;352(9131):854-65
references.pmid: 9742977
references.citation: J Clin Endocrinol Metab. 1998 May;83(5):1818-20
references.pmid: 9589700
references.citation: Am Heart J. 2005 Jan;149(1):33-45
references.pmid: 15660032
references.citation: Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):624-30
references.pmid: 16357312
references.citation: Diabetes Care. 2005 Jul;28(7):1680-9
references.pmid: 15983320
references.citation: Endocr Pract. 2006 Jan-Feb;12 Suppl 1:142-7
references.pmid: 16627399
references.citation: Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):28-40
references.pmid: 16239592